Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenia Purpurpa (NYMC207)

This study is conducted by the New York Medical College and is open for newly diagnosed pediatric ITP patients between 1 year – 21 years of age who have bleeding symptoms and show no evidence of a recent infection. Platelet counts less than 20, 000 µL are required. A bone marrow biopsy is preferred but not required. The aim of the study is to determine the effect of early administration of Rituximab on relapse rates following treatment. To determine impact on quality of life, the kids ITP tools (KIT) will be used according to protocol.



back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo